Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Class A Common Shares
-
Shares outstanding
-
98,656,192
-
Number of holders
-
27
-
Total 13F shares, excl. options
-
5,796,080
-
Shares change
-
+4,187,589
-
Total reported value, excl. options
-
$10,710,997
-
Value change
-
+$7,739,960
-
Put/Call ratio
-
41.19%
-
Number of buys
-
17
-
Number of sells
-
-9
-
Price
-
$1.85
Significant Holders of Cardiol Therapeutics Inc. - Class A Common Shares (CRDL) as of Q4 2021
35 filings reported holding CRDL - Cardiol Therapeutics Inc. - Class A Common Shares as of Q4 2021.
Cardiol Therapeutics Inc. - Class A Common Shares (CRDL) has 27 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5,796,080 shares
of 98,656,192 outstanding shares and own 5.88% of the company stock.
Largest 10 shareholders include MMCAP International Inc. SPC (3,153,200 shares), Mirae Asset Global Investments Co., Ltd. (1,045,205 shares), Verition Fund Management LLC (457,732 shares), TWO SIGMA INVESTMENTS, LP (194,554 shares), CITADEL ADVISORS LLC (177,069 shares), GOLDMAN SACHS GROUP INC (126,100 shares), TWO SIGMA ADVISERS, LP (123,600 shares), SABBY MANAGEMENT, LLC (99,440 shares), RENAISSANCE TECHNOLOGIES LLC (93,000 shares), and JANE STREET GROUP, LLC (52,796 shares).
This table shows the top 27 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.